LFST (LifeStance Health Group) Research & Development: $0 Mil (TTM As of Mar. 2026)


LFST LifeStance Health Group Inc LFST
57 GF Score
Price $9.65
GF Value $8.22
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is LifeStance Health Group Research & Development?

LifeStance Health Group LFST +2.22% 57 Research & Development is $0 Mil as of Mar. 2026. GuruFocus rates LFST with a GF Score™ of 57/100 and a GF Value™ of $8.22 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. LifeStance Health Group's Research & Development for the three months ended in Mar. 2026 was $0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $0 Mil.

LifeStance Health Group  (NAS:LFST) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

LifeStance Health Group Research & Development Related Terms

LifeStance Health Group Research & Development Historical Data

* Premium members only.

The historical data trend for LifeStance Health Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LifeStance Health Group Research & Development Chart

LifeStance Health Group Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

LifeStance Health Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LFST
57GF Score
LifeStance Health Group Inc LFST
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LifeStance Health Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0 Mil mean?
LifeStance Health Group (LFST) has a Research & Development of $0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on LifeStance Health Group and its competitors.
Is LifeStance Health Group's Research & Development too high?
LifeStance Health Group's current Research & Development is $0 Mil. Overall, LifeStance Health Group has a GF Score™ of 57/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does LifeStance Health Group's Research & Development compare to NHC and BKD?
LifeStance Health Group's Research & Development of $0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on LifeStance Health Group and its competitors. LifeStance Health Group's current Research & Development is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LifeStance Health Group stock overvalued right now?
Based on GuruFocus' analysis, LifeStance Health Group (LFST) is currently considered Modestly Overvalued. The stock's GF Value™ is $8.22, compared to a current price of $9.65 — trading 17.4% above its estimated fair value. The current Research & Development is $0 Mil. LifeStance Health Group's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For LifeStance Health Group (LFST), the current Research & Development is $0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is LifeStance Health Group (LFST) Overvalued in 2026?

Based on GuruFocus' analysis, LifeStance Health Group stock appears to be overvalued. The current stock price of $9.65 is trading 17.4% above its estimated GF Value™ of $8.22. GuruFocus considers LifeStance Health Group to be Modestly Overvalued.

Key valuation signals for LFST:

  • Research & Development: $0 Mil
  • GF Value™: $8.22 vs. price of $9.65 (17.4% above fair value)
  • GF Score™: 57/100 with 5 warning signs

No single metric tells the full story. See the LFST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

LifeStance Health Group Business Description

Address 4800 North Scottsdale Road, Suite 2500, Scottsdale, AZ, USA, 85251
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family, and group therapy. It treats a broad range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder, using evidence-based approaches to ensure effective treatment. The group has a single operating and reportable segment of mental health services.
57GF Score

Get the complete analysis for LFST

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.65
Price
$8.22
GF Value